Preclinical and Clinical Modulation of Anticancer Drugs PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Preclinical and Clinical Modulation of Anticancer Drugs PDF full book. Access full book title Preclinical and Clinical Modulation of Anticancer Drugs by Kenneth D. Tew. Download full books in PDF and EPUB format.
Author: Kenneth D. Tew Publisher: CRC Press ISBN: 9780849372919 Category : Medical Languages : en Pages : 410
Book Description
Preclinical and Clinical Modulation of Anticancer Drugs focuses on the theoretical and practical approaches to designing and enacting modulation principles. Each class of anticancer drug and the different types of modulators used within each drug class are discussed within individual chapters. The molecular and biochemical rationale for the use of specific modulators is discussed in detail, and preclinical and clinical implications of the data are integrated into each chapter. Mechanisms of drug resistance and the reasons behind circumventing the resistant phenotype are covered. The book will interest cancer chemotherapists, pharmacologists, oncologists, biochemists, and experimental therapeutics researchers, in addition to students studying the principles of drug discovery and protocol design.
Author: Kenneth D. Tew Publisher: CRC Press ISBN: 9780849372919 Category : Medical Languages : en Pages : 410
Book Description
Preclinical and Clinical Modulation of Anticancer Drugs focuses on the theoretical and practical approaches to designing and enacting modulation principles. Each class of anticancer drug and the different types of modulators used within each drug class are discussed within individual chapters. The molecular and biochemical rationale for the use of specific modulators is discussed in detail, and preclinical and clinical implications of the data are integrated into each chapter. Mechanisms of drug resistance and the reasons behind circumventing the resistant phenotype are covered. The book will interest cancer chemotherapists, pharmacologists, oncologists, biochemists, and experimental therapeutics researchers, in addition to students studying the principles of drug discovery and protocol design.
Author: Beverly A. Teicher Publisher: Springer Science & Business Media ISBN: 1461581524 Category : Medical Languages : en Pages : 315
Book Description
Experienced cancer researchers from pharmaceutical companies, government laboratories, and academia comprehensively review and describe the arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. They also define each stage of clinical testing, explain the criteria for success, and outline the requirements for FDA approval. A companion volume by the same editor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Author: Bruce C. Baguley Publisher: Elsevier ISBN: 0080490441 Category : Medical Languages : en Pages : 411
Book Description
Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. - One work that can be consulted for all aspects of anticancer drug development - Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts - A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death - Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products - Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques - Hundreds of references that allow the reader to access relevant scientific and medical literature - Clear illustrations, some in color, that provide both understanding of the field and material for teaching
Author: William D. Figg Publisher: Springer Science & Business Media ISBN: 1592597343 Category : Medical Languages : en Pages : 623
Book Description
Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.
Author: Frederick A. Valeriote Publisher: Springer ISBN: 9781461323327 Category : Medical Languages : en Pages : 350
Book Description
Biochemical Modulation at the present time defines an area of study in which the intracellular metabolism of a given anti cancer agent is modulated (usually by a noncytotoxic agent or a cytotoxic agent at sufficiently low dosage to make it non cytotoxic) in order to either increase the effectiveness of the particular agent against tumor cells or decrease its cytotox icity against normal cells. The major focus of modulation has been the agents 5-fluorouracil (FUra), arabinofuranosylcytosine (ara-C), methotrexate (MTX) and a few alkylating agents. The major thrust of the studies has been to increase the flow of the anticancer agent along the pathway responsible for the formation of the cytotoxic species: for example, FUra to FUTP or ara-C to ara-CTP. While in most cases the application of research re sults to clinical trials does not require the subsequent exper tise of the laboratory researchers, application of biochemical modulatory schemes to clinical protocols necessitate a dramatic break with the past procedures. As shown in the laboratory clinical loop below, close collaboration between the laboratory and clinical investigator is essential. While the laboratory REDEFINE TECHNOLOGY, TESTS OR QUESTIONS FOR FURTHER THERAPEUTIC ADVANCE CLINICAL EXPERIMENTAL PROTOCOL (LABORATORY) RESEARCH STUDIES DEFINE AND TEST APPROPRIATE SCIENTIFIC PARAMETERS results define rationally-based regimens, it is essential that the clinical protocols contain the requirement that clinical material (either tumor or normal tissues) be sampled to deter mine whether the biochemical modulation being proposed is in fact beinq accomplished.
Author: Raphael Mechoulam Publisher: CRC Press ISBN: 0429536267 Category : Medical Languages : en Pages : 276
Book Description
Published in 1986: The plant Cannabis sativa L. and its numerous preparations have been used as therapeutic agents for millenia. In the present book, the editor has tried to summarize the use in the past, to present an overview of modern research and applications to predict future developments.
Author: Robert C. Bast, Jr. Publisher: John Wiley & Sons ISBN: 111900084X Category : Medical Languages : en Pages : 2004
Book Description
Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Author: William D. Figg Publisher: Springer Science & Business Media ISBN: 0387715185 Category : Medical Languages : en Pages : 592
Book Description
Dr. Judah Folkman is considered the "father of angiogenesis." Because of Folkman's discovery and research, the possibilities of angiogenic therapy have broadened beyond cancer to many noncancerous diseases. Angiogenesis: An Integrative Approach from Science to Medicine is a comprehensive, concise summary of tumor angiogenesis. It is an up-to-date and authoritative reference for the angiogenesis field as it relates to oncology. This book represents the first collection in a volume of which Folkman is co-editor. Folkman has authored nearly 400 original papers and more than 100 book chapters.
Author: Kenneth D. Tew
Author: Kenneth D. Tew
Author: Beverly A. Teicher
Author: Bruce C. Baguley
Author: William D. Figg
Author: Ann L. Jackman
Author: Frederick A. Valeriote
Author: Roosje Lizelot Oostendorp.
Author: Raphael Mechoulam
Author: Robert C. Bast, Jr.
Author: William D. Figg